To print: Select File and then Print from your browser's menu

Title: Luteal Phase Sertraline Curbs Premenstrual Dysphoric Disorder

URL: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=R
Retrieve&db=PubMed&list_uids=12468166&dopt=Abstract

Obstet Gynecol 2002 Dec;100(6):1219-29. "Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder1."
12/23/2002 01:42:33 PM
By Anne MacLennan

Intermittently administered sertraline is significantly more effective than is placebo for premenstrual dysphoric disorder during the luteal phase of the menstrual cycle. It is also well tolerated, suggest Dr U Halbreich and colleagues from the State University of New York at Buffalo School of Medicine, Buffalo, New York, United States. Their goal was to evaluate the efficacy and tolerability of sertraline in premenstrual dysphoric disorder when treatment was limited to the luteal phase. Study participants were 281 women with this menstrually-related condition that intermittently causes disabling emotional, behavioural and physical symptoms. (All met Diagnostic and Statistical Manual of Mental Disorders [4th edition] criteria). The subjects completed two prospective screening cycles and one single-blind placebo cycle and were then randomised to three cycles of double blind, luteal phase treatment with either a placebo or sertraline in a flexible daily dose of 50 mg to 100 mg. Outcome measures included the Daily Record of Severity of Problems and the Clinical Global Impression Severity and Improvement scales. The significant superiority of luteal phase treatment with sertraline versus placebo was demonstrated by end-point analysis of Clinical Global Impression Improvement scale scores (sertraline, 2.3 ą 1.1, versus placebo, 2.7 ą 1.1; P <.001), and cycle three Daily Record of Severity of Problems change scores (sertraline, 27.6 ą 26.8, versus placebo, 17.6 ą 23.3; P <.002). There was also a significant difference in responder rates in favour of sertraline (50 percent) versus placebo (26 percent, P <.001) by cycle one. (Responder was defined as a Clinical Global Impression Improvement scale score of one or two.) In addition, quality of life and functioning outcomes were significantly improved by the drug. About eight percent of patients on sertraline, and less than one percent on placebo, discontinued treatment because of adverse events.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=R
Retrieve&db=PubMed&list_uids=12468166&dopt=Abstract

Copyright Š 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.